Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$2.88−0.15 (-4.95%)
Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –
Protalix BioTherapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
For fiscal 2014 it was $912.00K, down 61.5% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $912.00K | -61.5% |
| FY2013 | Dec 31, 2013 | $2.37M | -56.3% |
| FY2012 | Dec 31, 2012 | $5.43M | -17.4% |
| FY2011 | Dec 31, 2011 | $6.57M | – |
See a number that looks wrong?